The European Association for the Study of the Liver (EASL) held its 2016 Annual Meeting, “The International Liver Congress,” in Barcelona, Spain on April 13th-17th and Biomedtracker was in attendance. Below we highlight the key results from oral presentations and summarize the overarching themes of EASL 2016. The following report provides an overview of important data events at EASL 2016 with BMT commentary and analysis. This report includes data from a Biomedtracker Physician Pulse Survey of 31 US and 28 EU hepatologists and gastroenterologists. The full results of this survey is posted here. To purchase an add- on subscription to all hepatitis C virus (HCV) reports and surveys on KOL Insight, please email Client Services.

• Updated Phase II results of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype (GT) 1-6 HCV-infected patients, including those previously treated with direct-acting antiviral (DAA), showed >97% SVR12 in all patients regardless of cirrhosis status or genotype (GILD).
  
  
• Top-line results from Phase II MAGELLAN-I study of retreatment with glecaprevir/pibrentasvir with or without ribavirin showed >90% SVR12 in HCV-infected GT1 patients who have failed DAA-containing regimens (ABBV).
  
  
• Updated results from Phase II SURVEYOR-I and SURVEYOR-II trials showed that 8 weeks of glecaprevir/pibrentasvir resulted in 97% SVR12 in GT3 patients without cirrhosis, and 12 weeks of therapy resulted in 100% SVR12 in GT3 early-cirrhotic patients (ABBV).
  
  
• Interim Phase II results for two subcutaneous injections of RG-101 in combination with 4 weeks of DAA (Harvoni, Daklinza, or Olysio) showed >90% HCV RNA below limit of detection at 8 weeks and at 12 weeks in the portion of the population tested for treatment-naive GT1 and 4 HCV-infected patients (RGLS).
  
  
• Gilead announced 48-week results from two large, Phase III clinical trials (Studies 108 and 110) evaluating once-daily tenofovir alafenamide (TAF) 25 mg, a prodrug of approved Viread (tenofovir disoproxil fumarate, TDF) in treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic hepatitis B virus (HBV). These data showed non-inferiority head-to-head with Viread on long-term safety in bone density and renal measures (GILD).
  
  
• Top-line results from the Phase II LOWR-2 study investigating optimal dosing of lonafarnib with ritonavir for the treatment of chronic hepatitis delta virus (HDV) and reported viral load reductions with 12 to 24 week treatments. Following presentation of these data at EASL, Eiger announced the acquisition of interferon lambda from Bristol Meyers for future combination studies (EIGR).

For our disclosures, please read the BioMedTracker Research Standards.